Defining Treatment-Emergent Adverse Events with the Medical Dictionary for Regulatory Activities (MedDRA) *

Abstract

Summaries of safety data collected in a clinical trial typically include an analysis of the crude rate of treatment-emergent signs and symptoms. This paper outlines the issues in defining treatment-emergent events and discusses the impact of choosing different methodologies for event classification and data collection. It also relates these issues to the adoption of the Medical Dictionary for Regulatory Activities (MedDRA) as the standard coding dictionary for regulatory reports. While pharmaceutical companies are addressing the conversion of their existing dictionary system to MedDRA, it may be beneficial to address the issue of defining treatment-emergent so that any changes can be incorporated at the same time. Examples and recommendations are provided.

Keywords

Treatment-emergent MedDRA Adverse events Preferred term Lowest level term

Get full access to this article

View all access options for this article.

References

Chuang-Stein

Safety analysis in controlled clinical trials. Drug Inf J. 1998;32:1363S–1372S.

Chuang-Stein

Safety analysis: Too much? not enough? and how?

Biopharmaceut Report. 1992;1(No.3):1–11.

Gait

Smith

Brown

Evaluation of safety data from controlled clinical trials: The clinical principles explained. Drug Inf J. 2000;34:273–287.

Tremmel

Describing risk in long-term clinical trials. Biopharmaceut Report. 1996;4(2):5–8.

O'Neill

Assessment of safety. In Biopharmaceutical Statistics for Drug Development. Peace

, ed. New York, NY: Marcel Dekker;1988:543–604.

Offen

Statistical evaluation of adverse events. In American Statistical Association Proceedings of the Biopharmaceutical Section. Alexandria, VA: American Statistical Association; 1988:1–6.

Brown

Wood

The medical dictionary for regulatory activities (MedDRA). Drug Safety. 1999;20(2):109–117.

Goldstein

Wilson

Adverse event frequencies generate hypotheses of efficacy and safety. Clin Pharmacol Ther. 1993;54:245–251.

White

A preliminary assessment of the impact of MedDRA on adverse event reports and product labeling. Drug Inf J. 1998;32:347–362.